Latest news with #ARV-102
Yahoo
28-04-2025
- Business
- Yahoo
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under 'Events and Presentations' on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at following the completion of the event. About ArvinasArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X. Contacts Investors:Jeff Boyle+1 (347) Media: Kirsten Owens+1 (203) in to access your portfolio
Yahoo
04-04-2025
- Health
- Yahoo
Arvinas' PROTAC halves protein suspected to play role in Parkinson's
A first-in-human trial of Arvinas' investigational Parkinson's' disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the disease whilst also surpassing the blood-brain barrier. The Phase I single ascending dose (SAD) and multiple ascending dose (MAD) trial (EUCT-2023-507910-28-00) found ARV-102, a proteolysis targeting chimaera (PROTAC) therapy, led to a drop in leucine-rich repeat kinase 2 (LRRK2) across healthy volunteers. LRRK2 is associated with an increased risk of both autosomal dominant Parkinson's disease and Crohn's disease. In the SAD cohort, a single oral dose of at least 60mg of ARV-102, alongside further once daily repeated oral doses of at least 20mg, achieved greater than 50% LRRK2 reduction in the volunteer's cerebral spinal fluid. As well as a more than 90% LRRK2 reduction in the peripheral blood mononuclear cells (PBMCs). Investigation in the MAD cohort is still ongoing. Additional results from the SAD cohort found that ARV-102 at single doses of more than 30mg induced more than 50% decrease in peripheral phosphor-Rab10, a biomarker used to determine the therapy's ability to impact downstream of the blood-brain barrier. Noah Berkowitz, CMO at Arvinas, said: 'The ability of ARV-102 to cross the blood-brain barrier and degrade the LRRK2 protein offers a potentially transformative therapeutic approach in the treatment of devastating neurodegenerative diseases. 'We believe these results support continuing our ARV-102 clinical program and building upon our body of evidence for this lead PROTAC degrader candidate in our neuroscience pipeline.' Results from the randomised, double-blind, placebo-controlled were initially announced as part of the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Vienna, Austria. In the Phase I trial, the therapy was relatively well tolerated, with some adverse events (AEs) reported. Approximately 47 volunteers were recruited across all SAD dose levels with headaches reported in 17.1% of patients. Procedural pain associated with the lumbar puncture occurred in 28.6% of treated volunteers compared to 41.7% in placebo controls. This comes weeks after Arvinas' stock took a 51% after its PROTAC therapy for human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, being developed with pharma giant Pfizer, saw mixed results as it was only able to extend progression-free survival (PFS) in certain patients. The trial was conducted as part of a $2.4bn partnership between the companies. This latest Parkinson's data gives renewed hope to Arvinas for PROTAC therapies. Elsewhere in the field of Parkinson's disease therapies, Cerevance is continuing an ongoing pivotal study of its Parkinson's candidate despite it showing no benefit compared to placebo in a Phase II study. "Arvinas' PROTAC halves protein suspected to play role in Parkinson's" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
14-03-2025
- Business
- Yahoo
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Arvinas (ARVN), 924% surge in interest Janux Therapeutics (JANX), 479% surge in interest Fortress Biotech (FBIO), 440% surge in interest Dogwood Therapeutics (DWTX), 248% surge in interest Hepion Pharmaceuticals (HEPA), 219% surge in interest Tenaya Therapeutics (TNYA), 209% surge in interest Coherus BioSciences (CHRS), 185% surge in interest Aligos Therapeutics (ALGS), 165% surge in interest Beam Therapeutics (BEAM), 131% surge in interest NKGen Biotech (NKGN), 130% surge in interest Pipeline and key clinical candidates for these companies: Arvinas is a clinical-stage biotechnology company that says it is 'dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.' In addition to its preclinical pipeline of PROTAC protein degraders against validated and 'undruggable' targets, the company has four investigational clinical-stage programs: vepdegestrant for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-102 for the treatment of patients with neurodegenerative disorders. Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux's proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. Fortress Biotech is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has nine marketed prescription pharmaceutical products and over 30 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy. Dogwood Therapeutics is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on our lead development candidate, Halneuron which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of anti-herpes antivirals and the anti-inflammatory agent, celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia and Long-COVID. Hepion Pharmaceuticals is a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis, hepatocellular carcinoma, and other chronic liver diseases. Hepion's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH. Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction, and multiple early-stage programs in preclinical development. Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Coherus' immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Aligos Therapeutics is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, and coronaviruses. Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. Recent news on these stocks: March 12 Dogwood Therapeutics entered into a securities purchase agreement with certain institutional investors to purchase 578,950 shares of common stock at an offering price of $8.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds for the offering are expected to be approximately $4.8M before deducting placement agent fees and other offering expenses. This offering is expected to close on March 14, 2025, subject to customary closing conditions. Dogwood intends to use the net proceeds of this offering to further advance the clinical development of its lead development candidate, Halneuron, and for working capital and general corporate purposes. Maxim Group is acting as sole placement agent in connection with the offering. March 11 Arvinas and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative dvanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase 4/6 inhibitors and endocrine therapy. These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera ER degrader. The trial met its primary endpoint in the estrogen receptor 1-mutant population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat population. Overall survival was not mature at the time of the analysis, with less than a quarter of the required number of events having occurred. The trial will continue to assess overall survival as a key secondary endpoint. In the trial, vepdegestrant was generally well tolerated and its safety profile was consistent with what has been observed in previous studies. March 10 Checkpoint Therapeutics and Sun Pharmaceutical Industries announced on March 9 that they have entered into an agreement by which Sun Pharma will acquire the immunotherapy and targeted oncology company. Upon completion of the transaction, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right, or CVR, entitling the stockholder to receive up to an additional 70c in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom, subject to the terms and conditions in the contingent value rights agreement. Tenaya reported better-than-expected Q4 earnings per share. 'Throughout 2024, Tenaya made important advances across our cardiovascular gene therapy development pipeline that have positioned us for a data-rich 2025. We look forward to sharing data from both the TN-201 MyPEAK-1 clinical trial for MYBPC3-associated HCM and the RIDGE-1 clinical trial of TN-401 for PKP2-associated ARVC in the months ahead,' said Faraz Ali, Chief Executive Officer of Tenaya. 'The recent financing with support from existing and new shareholders allows us to maintain our focus on driving our gene therapy programs for cardiomyopathies toward later-stage development. In the first half of next year, we expect to have greater than one-year of follow-up in the high-dose cohort of MyPEAK-1, as well as one-year follow-up for the first few patients enrolled in the RIDGE-1 clinical trial.' Coherus Biosciences reportetd mixed Q4 results and announced it would reduce its headcount by 30%. The company said, 'Coherus projects post-UDENYCA-close cash of approximately $250 million and cash runway projections exceeding two years, past key data readouts expected in 2026. Approximately 50 employees associated with UDENYCA are expected to transfer to Accord BioPharma, Inc. as part of the asset purchase agreement and Coherus' headcount will be reduced by approximately 30% following the transaction to approximately 155.' Aligos reported a year-over-year decline in Q4 earnings per share, thtough revenue was higher year-over-year. '2024 was a pivotal year for the company, paving the way for the future of Aligos,' stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. 'That future looks bright as we move ALG-000184 closer towards a Phase 2 clinical study, which is expected to begin in mid-2025. We continue to believe our CAM-E has the potential to be a first- and best-in-class candidate, by acting as a disease modifying agent for patients in need of better outcomes. Our recent fundraising is backed by investors supportive of our vision for ALG-000184, which has the potential to replace standard of care and become the backbone of treatment for next-generation therapies for chronic hepatitis B virus infection.' Beam Therapeutics announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency and for in vivo base editing. Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable dose-dependent correction of the disease-causing mutation. Treatment with BEAM-302 was well tolerated with an acceptable safety profile at all dose levels explored to date. All adverse events were mild to moderate, with no serious AEs reported and no dose-limiting toxicities as of the data cutoff. Grade 1 asymptomatic alanine transaminase and aspartate aminotransferase elevations and transient Grade 1 infusion-related reactions were observed in some patients and did not require treatment. Following a single infusion of BEAM-302, rapid, durable, and dose-dependent increases in total AAT, new production of corrected M-AAT, and decreases in mutant Z-AAT were observed in circulation. Changes in total AAT were observed by turbidimetry assays as early as Day 7, plateaued around Day 21 and were maintained for the duration of follow-up. Increased total AAT was functional as determined by both neutrophil elastase inhibition and neutrophil elastase binding assays. Hear more from InvestingChannel by signing up for The Spill. About 'Biotech Alert' The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel. This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem. This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on PFE: Questions or Comments about the article? Write to editor@ Arvinas price target lowered to $12 from $48 at Morgan Stanley ViiV announces new study data showing zero HIV cases with Apretude ViiV Healthcare announces data from EMBRACE Phase IIb study Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint in Phase 3 trial Pfizer, Walmart, Super Micro, Salesforce, AbbVie: Insider Moves Unveiled! Sign in to access your portfolio
